These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
629 related items for PubMed ID: 20386071
1. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A. Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071 [Abstract] [Full Text] [Related]
2. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group. Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319 [Abstract] [Full Text] [Related]
3. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group. Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216 [Abstract] [Full Text] [Related]
4. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Moore RD, Keruly JC. Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456 [Abstract] [Full Text] [Related]
5. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. León A, Martinez E, Milinkovic A, Mora B, Mallolas J, Blanco JL, Larrousse M, Laguno M, Gallart T, Plana M, Gatell JM, Garcia F. J Antimicrob Chemother; 2009 Jan 01; 63(1):184-8. PubMed ID: 19001447 [Abstract] [Full Text] [Related]
6. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study. Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS. Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166 [Abstract] [Full Text] [Related]
7. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy. Stone SF, Price P, French MA. HIV Med; 2005 Jul 20; 6(4):278-83. PubMed ID: 16011533 [Abstract] [Full Text] [Related]
8. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group. Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251 [Abstract] [Full Text] [Related]
9. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy. Moore DM, Hogg RS, Braitstein P, Wood E, Yip B, Montaner JS. Antivir Ther; 2006 Jun 15; 11(1):125-9. PubMed ID: 16518968 [Abstract] [Full Text] [Related]
10. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. Le Moing V, Thiébaut R, Chêne G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaïed F, Leport C, Raffi F, ANRS CO8 (APROCO/COPILOTE) Study Group. HIV Med; 2007 Apr 15; 8(3):156-63. PubMed ID: 17461859 [Abstract] [Full Text] [Related]
11. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC. HIV Med; 2006 Mar 15; 7(2):99-104. PubMed ID: 16420254 [Abstract] [Full Text] [Related]
12. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients]. Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL. Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327 [Abstract] [Full Text] [Related]
13. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. Keane NM, Price P, Lee S, Almeida CA, Stone SF, James I, French MA. HIV Med; 2004 Nov 13; 5(6):407-14. PubMed ID: 15544692 [Abstract] [Full Text] [Related]
14. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency. Micheloud D, Berenguer J, Bellón JM, Miralles P, Cosin J, de Quiros JC, Conde MS, Muñoz-Fernández MA, Resino S. J Infect; 2008 Feb 13; 56(2):130-6. PubMed ID: 18192020 [Abstract] [Full Text] [Related]
15. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study. Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328 [Abstract] [Full Text] [Related]
16. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro. Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O. HIV Med; 2007 Mar 15; 8(2):75-9. PubMed ID: 17352762 [Abstract] [Full Text] [Related]
17. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, Chen KT, Yawetz S, Pacheco S, Davenny K, Adeniyi-Jones S, Thomas DL. Clin Infect Dis; 2005 Mar 15; 40(6):859-67. PubMed ID: 15736020 [Abstract] [Full Text] [Related]
18. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. AIDS; 2006 May 12; 20(8):1117-23. PubMed ID: 16691062 [Abstract] [Full Text] [Related]
19. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3. Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort. Antivir Ther; 2007 May 12; 12(6):941-7. PubMed ID: 17926648 [Abstract] [Full Text] [Related]
20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study. Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534 [Abstract] [Full Text] [Related] Page: [Next] [New Search]